Loading the section…
The price of ACADIA Pharmaceuticals Inc. (ACAD) on October 9, 2026 is 19.78 USD, +1.02% on the day. Over 52 weeks the stock traded between 19.32 USD and 30.96 USD; the price now sits 4% of the way up that range. Over the past year the price changed by -7.18%. The P/E ratio is 9.0, which is below the sector median (25.0). Market capitalization is 3.38 billion USD, rank 52 among 372 stocks of the same industry with a known capitalization.
Closing prices for 9 October 2026
Next earnings report: 4 November 2026 · Earnings calendar
Change over the period shown (line colour): −1.40 %
ACADIA Pharmaceuticals Inc. trades on Nasdaq under the ticker ACAD. The company belongs to the Health care sector. The trading history on this page starts on 22 August 2016.
Over the past 52 weeks ACAD has traded between 19.32 $ and 30.96 $. As of 9 October 2026 the price stood 3.95 % of the way from the 52-week low to the high.
Over one year ACAD shares fell 7.18 %; over six months they fell 9.02 %. Volatility over 90 days is 41.94 %. Dividends are not included: this is price change only, as of 9 October 2026.
ACAD trades at a price-to-earnings ratio of 9.0, below the sector median of 25.0. Price to sales is 3.1, below the sector median of 4.0. Price to book is 2.7, above the sector median of 2.5. Calculated from reports for the period ending 31 March 2026.
| Date | Open | High | Low | Close | Volume, shares |
|---|---|---|---|---|---|
| 9 October 2026 | 19.60 | 20.05 | 19.58 | 19.78 | 1M |
| 8 October 2026 | 19.46 | 19.79 | 19.32 | 19.58 | 2M |
| 7 October 2026 | 19.60 | 19.80 | 19.46 | 19.65 | 2M |
| 6 October 2026 | 20.16 | 20.36 |
The series is stated in the current share scale after splits; dividends are not included in the price
Based on the last 12 months of reports, through 31 March 2026
The sector median covers every company in the sector on the US market, loss-making ones included.
ACADIA Pharmaceuticals Inc. (ACAD) is a public company in the healthcare sector. Its common stock trade on NASDAQ.
Over the trailing twelve months as reported to 2026-03-31, revenue was 1.1bn $, net income was 375.6m $. Incorporated in US.
This summary is compiled automatically from SEC filings and exchange data.
Address:12830 EL CAMINO REAL SUITE 400, SAN DIEGO, CA, 92130, US
ACADIA Pharmaceuticals Inc. reported revenue of 1.1B $ and net income of 376M $ over the last four quarters. Net margin is 34.30 %. Revenue changed by +9.93 % year over year. Earnings per share are 2.21 $. Market capitalisation is 3.4B $.
ACAD has a return on equity of 30.10 %, above the sector median of −41.68 %. Return on assets is 23.40 %, above the sector median of −32.11 %. Operating margin is 7.39 %, above the sector median of −26.84 %.
| 1.2B |
| PFEPfizer, Inc. | 28.28 | +1.65 % | 922M |
| ABTAbbott Laboratories | 99.60 | +1.13 % | 921M |
| BMYBristol-Myers Squibb Company | 59.12 | −0.77 % | 714M |
| REGNRegeneron Pharmaceuticals, Inc. | 746.54 | +0.94 % | 555M |
| 19.67 |
| 19.74 |
| 2M |
| 5 October 2026 | 20.05 | 20.45 | 19.57 | 20.11 | 3M |
| 2 October 2026 | 20.01 | 20.24 | 19.88 | 19.95 | 3M |
| 1 October 2026 | 19.95 | 20.19 | 19.59 | 19.89 | 3M |
| 30 September 2026 | 20.28 | 20.70 | 19.93 | 20.15 | 3M |
| 29 September 2026 | 20.61 | 20.61 | 20.06 | 20.22 | 3M |
| 28 September 2026 | 20.53 | 20.63 | 19.80 | 20.53 | 4M |
| 25 September 2026 | 22.21 | 22.21 | 20.61 | 20.68 | 3M |
| 24 September 2026 | 24.38 | 24.38 | 21.97 | 22.18 | 7M |
| 23 September 2026 | 26.41 | 26.51 | 24.93 | 25.43 | 1M |
| 22 September 2026 | 26.65 | 26.86 | 26.32 | 26.41 | 1M |
| 21 September 2026 | 27.43 | 27.43 | 26.34 | 26.40 | 1M |
| 18 September 2026 | 27.37 | 27.48 | 26.73 | 27.29 | 5M |
| 17 September 2026 | 27.78 | 28.06 | 27.29 | 27.45 | 1M |
| 16 September 2026 | 26.75 | 27.60 | 26.66 | 27.54 | 1M |
| 15 September 2026 | 27.51 | 27.51 | 26.64 | 26.76 | 1M |
| 14 September 2026 | 28.00 | 28.10 | 27.38 | 27.52 | 2M |